AZD5363+Olaparib+Durvalumab
Phase 1Monoclonal antibody
AZD5363+Olaparib+Durvalumab is one of 4 small molecule programs targeting Advanced or Metastatic Solid Tumor Malignancies. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Advanced or Metastatic Solid Tumor Malignancies
#DrugCompanyPhaseTrials
1NP-G2-044
NNovita Pharmaceuticals, Inc.
Phase 2
Anti-PD-1 Therapy
NNovita Pharmaceuticals, Inc.
Phase 2
Chemotherapy Drug
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Preclinical
AZD5363+Olaparib+Durvalumab
NNational University Hospital, Singapore
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AZD5363+Olaparib+Durvalumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details